Alex Zhavoronkov

Biography
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened RD centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 21 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule. Since 2012, he has published over 200 peer-reviewed research papers and 3 books. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Wellness & Aging Showcase:
Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems.

Sara Hägg

Biography
Associate professor in molecular epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet and my research is about aging. I use data from the Swedish Twin Registry and the UK Biobank to look at biological aging and associations with age-related diseases.

Luigi Ferrucci

Biography
Dr. Luigi Ferrucci is a geriatrician and an epidemiologist who conducts research on the causal pathways leading to progressive physical and cognitive decline in older persons. In September 2002, he became the Chief of the Longitudinal Studies Section at NIA and the Director of the Baltimore Longitudinal Study on Aging. Medical Degree and Board Certification in 1980, Board Certification in Geriatrics in 1982 and Ph.D. in Biology and Pathophysiology of Aging in 1998 at the University of Florence, Italy. Principal Investigator of the InCHIANTI study and of the Baltimore Longitudinal Study on Aging. Dr. Ferrucci is Scientific Director, NIA since May 2011.

Sherry Zhang

Biography
Yi Sherry Zhang is a genomics scientist and health-tech entrepreneur advancing the translation of longevity science into scalable population impact. At the Buck Institute for Research on Aging, she leads the development of Healthspan Horizons, a federated AI and biodata platform integrating multi-omics, digital, and clinical signals to quantify and extend healthy human lifespan. Drawing on nearly two decades of experience at the intersection of molecular science, data intelligence, and personalized health, she previously founded GenoPalate, which built one of the worlds largest nutrigenomics databases and consumer platforms for precision nutrition. Her work bridges molecular biomarkers and actionable lifestyle insights, with publications and features spanning scientific and public domains. An advocate for equitable access to scientific wellness, she speaks globally on data federation, precision aging, and the future of healthspan intelligence.

David A. Sinclair

Biography
David A. Sinclair, A.O., Ph.D. is considered one of the worlds most influential scientists and a leading figure in the study of human longevity. He is a tenured Professor of Genetics at Harvard Medical School (Boston, MA, USA) and Co-Founder Co-Chief Editor of the scientific journal Aging.Professor Sinclairs pioneering work in genetics and aging biology has fundamentally shaped the worlds understanding of mechanisms of aging and age-related diseases. He is best known for his research on the molecular biology of aging, particularly the role of sirtuins, NAD+ metabolism, and epigenetic changes in regulating the aging process. In 2020, the Sinclair Lab reported successful use of cellular reprogramming to safely reverse aging in mammals, which they showed could cure blindness in animal models.Professor Sinclair served as Founding Director of the Glenn Center for Biology of Aging Research at Harvard Medical School from 2004 2023 and has published over 400 articles that have been cited 100,000 times. He is the inventor on more than 50 patents and has co-founded over a dozen successful companies including MetroBiotech, EdenRoc Sciences, Fully Aligned Company, and Life Biosciences.Professor Sinclair is the New York Times bestselling author of Lifespan: Why We Age-And Why We Dont Have To and the host of the Lifespan with Dr. David Sinclair podcast, a 1 show on Apple that provides health and science education.Among over 35 career awards, Professor Sinclair has been recognized as one of TIME Magazines 100 Most Influential People In The World, one of TIMEs 50 Most Influential People In Health Care, received the Pioneer Award from the Director of the NIH, The Noble Genius Prize from The World Forum, and was appointed by Queen Elizabeths representative as Officer of the Order of Australia(A.O.) for his contributions to scientific research, science communication, and national security.

Nir Barzilai

Biography
Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aginghas its own biology that drives age-related diseases, a process that can be targeted. At AlbertEinstein College of Medicine, he is a professor in the departments of Medicine and Genetics,the director of the Institute for Aging Research, and the director of the Einstein-NationalInstitutes of Health (NIH) Nathan Shock Center of Excellence in the Basic Biology of Aging, andthe author of 350 papers. He made seminal discoveries in extending the health and lifespan ofanimals and discovering pathways for exceptional longevity in humans. He is leading aninternational effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) isa specific study conceived by Dr. Barzilai to prove that a single drug can combat multiplediseases associated with aging and get FDA approval for targeting aging. Dr. Barzilai is a co-founder and the President of AHLS. He is also on the board of directors of the AmericanFederation for Aging Research, where he co-leads its biomarker effort (FAST), TAME, andSuper Agers initiative. He is an Executive of the Longevity Biotech Association (LBA) andserves on the Healthy Longevity Medicine Society council. He authored Age Later: Health Span,Life Span, and the New Science of Longevity.

Stefan Horvath

Biography
Dr. Steve Horvath is a geroscientist and computational biologist best known for developing the epigenetic clock, a groundbreaking biomarker that measures biological aging based on DNA methylation patterns. His work has transformed aging research, enabling precise tracking of aging-related interventions and influencing diagnostics, longevity science, and precision medicine. Dr. Horvath has led key studies linking epigenetic age acceleration to disease risk and mortality, paving the way for potential anti-aging therapies. He has held leadership roles in major scientific initiatives and has received numerous honors, including election to the Academy for Health Lifespan Research, as well as the Nathan W. Shock Award for aging research. His contributions continue to shape the future of aging and longevity research, with broad applications in medicine and biotechnology.

Alex Zhavoronkov

Biography
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened RD centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 21 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule. Since 2012, he has published over 200 peer-reviewed research papers and 3 books. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.